This is a working overview of Dipeptidyl peptidase-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Moscow contains more than 21,500 Wi-Fi access points in student dormitories; in parks; at cultural and sports institutions; and within the Garden Ring and the Third Transport Ring. From September 2020 to August 2021, 1,700 public Wi-Fi access points were launched in Moscow. The structure of the city's Wi-Fi network allows residents to use the Internet without reauthorization.
DAS28: Disease Activity Score of 28 joints (DAS28) is widely used as an indicator of RA disease activity and response to treatment. Joints included are (bilaterally): proximal interphalangeal joints (10 joints), metacarpophalangeal joints (10), wrists (2), elbows (2), shoulders (2) and knees (2). When looking at these joints, both the number of joints with tenderness upon touching (TEN28) and swelling (SW28) are counted. The erythrocyte sedimentation rate (ESR) is measured, and the affected person makes a subjective assessment (SA) of disease activity during the preceding 7 days on a scale between 0 and 100, where 0 is "no activity" and 100 is "highest activity possible". With these parameters, DAS28 is calculated as:
Finally, a civilization known as "Type III" reaches the milepost set in 5,800 years when humanity's rate of energy consumption is predicted by the author to match the power emitted by the approximated 1011 stars in the Milky Way galaxy, which involves harnessing power of up to an estimated 4×1037 W. Assuming the development of radio, Kardashev predicted that in the following two decades (i.e. in the 1980s) it would be possible to build antennas of 100,000 m2 capable of detecting Type II and III civilizations. A Type I civilization like that of Earth would be able to receive the extraordinary energetic emissions of the other types of civilizations, which would supposedly be able to emit continuously. Kardashev then examined the characteristics of a transmission from an artificial source. He mentioned the two cosmic radio sources discovered in 1963 by the California Institute of Technology, CTA-21 and CTA-102 in particular, which would have characteristics close to those of a presumed artificial source. The most suitable region of the galaxy for observing Type II and III civilizations would then be the Galactic Center, due to the high density of the stellar population it harbors. He then recommended that the search programs for such artificial sources should focus on other nearby galaxies, such as the Andromeda Galaxy, the Magellanic Clouds, M87, or Centaurus A. Kardashev concluded his paper by noting that the possible discovery of even the simplest organisms on Mars would increase the likelihood that Type II civilizations exist in the galaxy.
Sources: en.wikipedia.org
Galactose a simple sugar which does not participate in the glucose metabolism control system. It is half of the disaccharide, lactose (milk sugar). Gangrene Infection of dead body tissue. It is most often caused by a loss of blood flow, especially in the legs and feet. Gangrene is particularly dangerous in that the infection cannot be reached by body defense systems and so can proceed without interference. Gastroparesis A form of nerve damage that affects the stomach and intestines. Food is not digested properly and does not move through in a normal way, resulting in vomiting, nausea, or bloating. It often interferes with diabetes management. See also: Autonomic neuropathy. Gene a unit of heredity. Eye color is a particularly simple system. There are blue eye genes and brown eye genes and one's eyes are brown if one of the two eye color genes is a brown one and blue if blue genes are inherited from both parents. Each gene is a segment of DNA and is often controlled by other genes. In the case of glucose absorption, the gene whose expressed protein opens the glucose ports in the cell wall is normally inhibited by another gene's product. We have finally come to understand the normal process in considerable detail; it is the same in nematode worms, fish, mice, pigs, cows, and people. Genetic See also: heredity. Gestation pregnancy and birth Gestational diabetes mellitus (GDM) A type of diabetes mellitus that can occur when a woman is pregnant. During the pregnancy (usually later in it), the woman may have glucose (sugar) in her blood at a higher than normal level.
Anne Ephrussi studied biology at Harvard University in the Department of Biochemistry and Molecular Biology from where she graduated in 1979. She continued to do her PhD at the Massachusetts Institute of Technology (MIT) in the group of Susumu Tonegawa where she received her doctoral degree in 1985. Ephrussi performed postdoctoral research at Harvard University in the lab of Thomas Maniatis from 1986 to 1989 and at the Whitehead Institute for Biomedical Research with Ruth Lehmann from 1989 to 1992. Since 1992, Anne Ephrussi has been a group leader at the European Molecular Biology Laboratory (EMBL). She became the head of EMBL International Centre for Advanced Training in 2005. She served as Associate Dean (1999 - 2005) and Dean (2005 - 2008) of Graduate Studies of the EMBL International PhD program and as head of the developmental biology unit (2007-2021). She is part of numerous international Scientific Advisory Boards and Panels, organizes international conferences and scientific meetings and evaluates research grant and fellowship applications for a variety of renowned funding bodies.
== Contraindications == Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or other drug-dependent individuals or those with comorbid psychiatric disorders. Additional caution is required in critically ill patients, as accumulation of midazolam and its active metabolites may occur. Kidney or liver impairments may slow down the elimination of midazolam leading to prolonged and enhanced effects.
=== Origin === Several scholars, including the historian and lawyer Michelle Alexander, have stated that the war on drugs is one product of a political strategy known as "tough on crime." The emergence of the initiative in conservative politics can be traced to American campaigns in the mid-1950s. A 1966 U.S. News & World Report article covering Nixon's presidential campaign quoted him as saying that "the increasing crime rate can be traced directly to the spread of the corrosive doctrine that every citizen possesses an inherent right to decide for himself which laws to obey and when to disobey them." In the 1960s, as Nixon was making his first presidential run, crime rates began to rise dramatically in the United States. Street crime reportedly quadrupled, and homicide rates nearly doubled. Alexander writes that while scholars now attribute the rising crime rates to the surge in population of the baby boomer generation, conservatives then tied the increases to race. Crime reports were used as evidence of a loss of morality and of social stability in the wake of the Civil Rights Movement. The 1964 Republican presidential candidate Barry Goldwater made the connection during his campaign and helped to lay the groundwork for the tough on crime movement. In a 1964 speech, "Peace through Strength," Goldwater said, "Choose the way of the Johnson Administration and you have the way of mobs in the streets." Lyndon Johnson's administration was responsible for passing the Civil Rights Act of 1964.
Sources: en.wikipedia.org
== Subunit interactions in tetramers == The interactions between subunits forming a tetramer is primarily determined by non covalent interaction. Hydrophobic effects, hydrogen bonds and electrostatic interactions are the primary sources for this binding process between subunits. For homotetrameric proteins such as sorbitol dehydrogenase (SDH), the structure is believed to have evolved going from a monomeric to a dimeric and finally a tetrameric structure in evolution. The binding process in SDH and many other tetrameric enzymes can be described by the gain in free energy which can be determined from the rate of association and dissociation. The above image shows the assembly of the four subunits (A,B,C and D) in SDH.
=== Nicaragua === The Castillo Administration refused to recognize the results of the 2021 Nicaraguan general election, saying it did not meet the minimum criteria for free elections. Free Peru's leader Vladimir Cerrón blamed Foreign Minister Óscar Maúrtua for the refusal to recognize Nicaragua's election. Cerrón released a statement saying "Regrettable position adopted by the Ministry of Foreign Affairs - Foreign Ministry of Peru, regarding the elections in Nicaragua, the same position adopted by the reactionary forces to ignore the electoral victory of Pedro Castillo."
In 1958, HVEC established High Voltage Engineering Europa (HVEE) in Amersfoort, Netherlands to supply accelerators to the European common market. The subsidiary was created in response to demand for accelerators in the European common market and export-controlled markets. HVEE manufactured HVEC's lower-voltage Van de Graaff accelerators for industries in the European common market, as well as insulated-core transformer power supplies for low-voltage electron beams. According to production records compiled through 2004, HVEE manufactured 93 accelerators across various voltage ranges, mostly in the 0.5–2 MV range. HVEE also produced smaller numbers of higher-voltage systems, including three accelerators in the 5–7 MV range and one in the 4-5 MV range. High Voltage Engineering Europa continued operations after its parent company's bankruptcy. HVEE produced low-voltage 1–5 MV, solid-state voltage generators with the trade names Tandetron and Singletron, originally designed by the General Ionix Corporation in Massachusetts. Having shifted away from belt-charged accelerators, HVEE's lower voltage accelerators now incorporate newer charging technologies.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.